Amgen posts more promising PCSK9 results; Takeda taps Natrogen for ulcerative colitis drug;

@FierceBiotech: Alimera, pSivida skyrocket as they give the thrice-rejected Iluvien another go. More | Follow @FierceBiotech

@JohnCFierce: Another day, another positive PhIII study for AMG 145 (PCSK9). Release | Follow @JohnCFierce

@DamianFierce: GSK and Theravance score another FDA approval with Anoro, a novel COPD combo therapy. News | Follow @DamianFierce

@EmilyMFierce: BRAIN Initiative announces 6 funding opportunities for biomedical researchers. More from FierceBiotech Research | Follow @EmilyMFierce

> Amgen's ($AMGN) PCSK9-blocking evolocumab met its primary endpoint in top-line results from a Phase III study, lowering LDL cholesterol by 52% after one year. More

> Baxter ($BAX) won FDA approval for Feiba, a prophylaxis treatment designed to reduce bleeding episodes in hemophilia patients who have developed inhibitors to traditional factor-replacement therapy. News

> Takeda has licensed a Phase II ulcerative colitis drug from Deerfield, IL's Natrogen, partnering up on an oral compound that inhibits pro-inflammatory cytokine expression. Release

Medical Device News

@FierceMedDev: Investors propel St. Jude Medical to new heights over 2013 rebound. Article | Follow @FierceMedDev

@MarkHFierce: So, how many device companies will go for FDA/CMS parallel review now that the pilot program has been extended? More | Follow @MarkHFierce

@MichaelGFierce: Synapse collects state-funded $2.4M for next-gen diaphragm pacing device. Item | Follow @MichaelGFierce

@GalenMoore: ICYMI: Despite tax hike, Medtronic's money still flies to Puerto Rico. Story | Follow @GalenMoore

> Decision Diagnostics is raising cash to keep its J&J glucose strip patent fight running. More

Pharma News

@FiercePharma: South Africa's top business daily accuses its state pension fund of protectionism vs. a $1.2B deal with Chile's CFR Pharma. More from Reuters | Follow @FiercePharma

@EricPFierce: AstraZeneca gets former Amylin plant & Bristol-Myers Ohio plant in breakup of diabetes venture. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: As GSK hails its FDA nod for Anoro, a Novartis Advair knockoff prepares for its close-up. Story | Follow @CarlyHFierce

> With a sweetened $2.9B bid, Bayer nabs its Xofigo partner, Algeta. Report

> Bristol-Myers bails out of 'Diabetes Inc.' in $4.1B sell-out to AstraZeneca. Story

> GlaxoSmithKline scores FDA nod for blockbuster COPD hopeful Anoro Ellipta. News

> Raised eyebrows at patient charity spotlight copay assistance debate. More

Pharma Manufacturing News

> Hacked off: Congress members, PhRMA urge an outside audit of the FDA data breach. Story

> Regeneron will invest $300M, hire 300 in its revamp of a Dell plant in Ireland. More

> The FDA and EU members will share some inspection duties. News

> AstraZeneca will take over 2 U.S. plants in its $4.1B diabetes drug transfer. Report

> CEO Nakayama says Daiichi Sankyo is helping Ranbaxy deal with the FDA's concerns. Article

> FDA puts veterinary drugs from banned Wockhardt plants on a leash. Item

Vaccines News

> Schulman leaves Pfizer weeks before start date of new top vaccine job. More

> CDC: Vaccines prevented 6M cases of flu, 79,000 hospitalizations last year. News

> Moderate alcohol consumption acts as vaccine adjuvant in monkeys. Article

> Physician failings raise doubts about the potency of U.K. vaccines. Story

> Agenus stock jumps on Phase II brain cancer vaccine data. Piece

> California calls for unapproved Bexsero to stop its meningitis outbreak. Item

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.